WEKO3
アイテム
Carbon Ion Radiotherapy in a Hypo-fractionation Regimen for Stage I Non-SmallCell Lung Cancer
https://repo.qst.go.jp/records/65006
https://repo.qst.go.jp/records/650062c5fe4f6-d3dc-4c72-b6de-0eb2dbde727c
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2013-05-23 | |||||
| タイトル | ||||||
| タイトル | Carbon Ion Radiotherapy in a Hypo-fractionation Regimen for Stage I Non-SmallCell Lung Cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Takahashi, Wataru
× Takahashi, Wataru× Yamamoto, Naoyoshi× Nakajima, Mio× Kamada, Tadashi× 高橋 渉× 山本 直敬× 中嶋 美緒× 鎌田 正 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | From 1994 to 1999, we conducted a phase I/II clinical trial for stage I non-small cell lung cancer (NSCLC) by using carbon ion beams alone, demonstrating optimal doses of 90.0GyE in 18 fractions over 6 weeks (Protocol #9303) and 72.0GyE in 9 fractions over 3 weeks ( #9701) for achieving more than 95% local control with minimal pulmonary damage. In the present study, the total dose was fixed at 72.0GyE in 9 fractions over 3 weeks (#9802), and at 52.8GyE for stage IA and 60.0GyE for stage 1B in 4 fractions in 1 week (#0001). Following this schedule, we conducted a phase II clinical trial for stage I NSCLC from 1999 to 2003. We also conducted a phase I/II single fractionation clinical trial (#0201), a dose escalation study. The total dose was initially 28.0GyE in 2003, and it was raised to 50.0GyE in 2011. The local control rate for all patients (#9802 and #0001) was 91.5%, and those for T1 and T2 tumors were 96.3% and 84.7%, respectively. The 5-year cause-specific survival rate was 67.0% (IA: 84.4, IB: 43.7), and overall survival was 45.3% (IA: 53.9, 1B: 34.2). No adverse effects greater than grade 2 occurred in the lung. In a single fractionation trial, the 5-year local control rate for 151 patients was 79.2%, and the control rates for T1 and T2 tumors were 83.6% and 72.2%, respectively. No adverse effects greater than grade 2 occurred in the lung. Carbon beam radiotherapy, an excellent new modality in terms of high QOL and ADL, was proven to be a valid alternative to surgery for stage I cancer, especially for elderly and inoperable patients. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Heavy Ion in Therapy and Space Radiation Symposium 2013(HITSRS2013) | |||||
| 発表年月日 | ||||||
| 日付 | 2013-05-18 | |||||
| 日付タイプ | Issued | |||||
